Frequency of cutaneous reactions on rechallenge with nevirapine and delavirdine

Annals of Pharmacotherapy

Volumn 34, Issue 7-8, 2000, Pages 839-842

  Gangar, Mona ^a   Arias, Gabriela ^a   O'Brien, John G ^a   Kemper, Carol A ^a,d  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b California Collaborative Treatment Group   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NONE

Author keywords

Delavirdine; Nevirapine; Rash

Indexed keywords

DELAVIRDINE; NEVIRAPINE;

ADULT; ARTICLE; DRUG HYPERSENSITIVITY; DRUG USE; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RASH; TREATMENT INDICATION; TREATMENT PLANNING;

ADULT; DELAVIRDINE; DRUG THERAPY, COMBINATION; EXANTHEMA; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; RECURRENCE; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS;

EID: 0033913743     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19258     Document Type: Article

References (17)

1. Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995;171:537-45.
2. de Jong MD, Vella S, Carr A, Boucher CAB, Imrie A, French M, et al. High-dose nevirapine in previously untreated human immunodeficiency virus type-1 infected persons does not result in sustained suppression of viral replication. J Infect Dis 1997;175:966-70.
3. Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS Trial. JAMA 1998;279:930-7.
4. Carr A, Vella S, de Jong MD, Sorice F, Imrie A, Boucher CA, et al. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian Study Group. AIDS 1996;10:635-41.
5. Davey RT Jr, Chaitt DG, Reed GF, Freimuth WW, Herpin BR, Metcalf JA, et al. Randomized, controlled Phase I/II trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 1996;40:1657-64.
6. Manufacturer's information. Rescriptor (delavirdine mesylate tablets). Kalamazoo, MI: Upjohn, August 1997.
7. Murri R, Antinori A, Camilli G, Zannoni G, Patriarca G. Fatal toxic epidermolysis induced by zidovudine. Clin Infect Dis 1995;23:640-1.
8. Warren KJ, Boxwell DE, Kim NY, Drolet BA. Nevirapine-associated Stevens-Johnson syndrome (letter). Lancet 1998;351:567.
9. D'Aquila RT, Hughes MD, Johnson VA, Fischl MA, Sommadossi JP, Liou S, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med 1996;124:1019-30.
10. Manufacturer's information. Management of rash associated with Viramune (nevirapine). Columbus, OH: Roxane Laboratories, September 1996.
11. Barner A, Myers M. Nevirapine and rashes (letter). Lancet 1998;351: 1133.
12. Been-Tiktak AM, Boucher CA, Brun-Vezinet F, Joly V, Mulder JW, Jost J, et al. Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian Phase II trial. Int J Antimicrob Agents 1999;11:13-21.
13. Bellman PC. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed. AIDS 1998;12:1333-40.
14. Bersoff-Matcha SJ, Miller WC, Van Der Horst C, Hamrick HJ Jr, Gase D, Powderly WG, et al. Gender differences in nevirapine rash (abstract #682). Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, January 31-February 4, 1999.
15. Derisi M, Bllard C, Abulhosn K, Colwell B, Barber E, Matthews C. Sulfa-associated rash and race are risk factors for non-nucleoside reverse transcriptase inhibitor (NNRTI)-associated rash (abstract #61). Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, January 30-February 3, 2000.
16. Kaspar R. Prednisone during the induction phase of nevirapine therapy appears to reduce the incidence of nevirapine associated rash (abstract #I-64a). Program and Abstracts for the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 24-27, 1998.
17. Freimuth WW. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Adv Exp Biol 1996;394:279-89.